CClinicalTrials.gg
RecruitingNCT06791603Updated Jan 24, 2025

The Impact of Social Media-delivered Chemotherapy Side Effects Education for Breast Cancer Patients Receiving Chemotherapy

An interventional study of Standardized chemotherapy education + video in Chemotherapy Side Effects, Social Media and Education of Patients, sponsored by Taipei Medical University Shuang Ho Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Taipei Medical University Shuang Ho Hospital · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if a standardized pharmacists-provided education module by social media can improve patients' knowledge of chemotherapy-related side effects. The main questions it aims to answer is:

  • Do patients who received a standardized pharmacists-provided education module by social media improve their knowledge of chemotherapy-related side effects? Researchers will compare standardized chemotherapy education +video (experimental group) versus chemotherapy handouts (control group).

Participants will:

  • Received standardized chemotherapy education + video or chemotherapy handouts at the first and second chemotherapy section.
  • Fill out a questionnaire for outcomes assessment.
Read the detailed description

The pharmacist-provided video education model for patients undergoing first time chemotherapy was developed. The content of the education video included the mechanism of side effects, its recognition, preventive measures, non-medical management, and further instructions when to visit hospital were included.

Patients were randomly assigned into two groups with different education strategies:

Standardized chemotherapy education +video (experimental group) versus chemotherapy handouts (control group). Every patient was asked to fill out a questionnaire prior to the implementation of the education model in both groups. The pre-test questionnaires consisted of baseline knowledge and personal information. Patients in the experimental group would receive standardized chemotherapy education by pharmacists, including chemotherapy regimen, the purpose of chemotherapy, the number of cycles, duration of chemotherapy and the common side effects of chemotherapy on the first day of chemotherapy cycle. Videos will be provided with patients and they will watch videos during the visit. The information regarding the prevention and management of side effects and further instructions when to visit hospital. Patients will have access to videos and watch videos after leaving the hospital for the entire treatment course. The education time will be last around 15 to 20 minutes. In terms of control group, pharmacists will briefly explain and provide chemotherapy handouts, including chemotherapy regimen, the purpose of chemotherapy, the number of cycles, duration of chemotherapy and the common side effects of chemotherapy. The duration of visit will be around 5 to 10 minutes. After the education section, patients will be asked to do a post-test questionnaire of their knowledge and quality of life.

02

Conditions studied

  • Chemotherapy Side Effects
  • Social Media
  • Education of Patients

Keywords

  • pharmacist
  • chemotherapy education
  • social media
03

In context

Lead sponsor

Taipei Medical University Shuang Ho Hospital is the lead sponsor of 100 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Breast cancer patients aged 18 or older undergoing their first chemotherapy.
  • Possess a smartphone and are able to watch videos on it.

Exclusion criteria

Exclusion Criteria:

  • Unable to read or complete questionnaires in Chinese.
  • Cognitive impairments.
  • Pregnant women.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Standardized chemotherapy education + video

    Standardized chemotherapy education+ video

    Other: Standardized chemotherapy education + video

  • No intervention
    Chemotherapy handouts

    Chemotherapy handouts

Interventions

  • OtherStandardized chemotherapy education + video

    Videos will be provided with patients and they will watch videos during the visit. The information regarding the prevention and management of side effects and further instructions when to visit hospital. Patients will have access to videos and watch videos after leaving the hospital for the entire treatment course

06

What researchers measure

Primary outcomes

  1. A questionnaire with 5 questions of side effects management

    Each question is a multiple choice with 4 options and 1 correct answer

    Time frame: 1. First time receiving chemotherapy 2. Second time receiving chemotherapy (3 to 4 weeks depend on schedule)

Secondary outcomes

  1. FACT-B, The Functional Assessment of Cancer Therapy - Breast

    Time frame: 1. First time receiving chemotherapy 2. Second time receiving chemotherapy (3 to 4 weeks depend on schedule)

07

Study locations

1 of 1 sites recruiting
  • Shuang Ho Hospital
    New Taipei City, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06791603
Lead sponsor
Taipei Medical University Shuang Ho Hospital
Responsible party
Pohung Lin (Principal Investigator, clinical pharmacist, Taipei Medical University Shuang Ho Hospital) — Principal investigator
First posted
Jan 24, 2025
Start date
Jan 6, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Jan 24, 2025

Study contacts

Pohung Lin, PharmD
Contact
19365@s.tmu.edu.tw
886-933-826-267
Pohung Lin, PharmD
principal investigator · Taipei Medical University Shuang Ho Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion